Andrew Wang

Journal Article Am Heart J · May 2026 BACKGROUND: Transcatheter tricuspid valve interventions (TTVI) have expanded with the recent FDA approval of both replacement transcatheter tricuspid valve replacement (TTVR) and edge-to-edge repair (T-TEER) devices. However, the volume and outcomes of com ... Full text Link to item Cite

Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.

Journal Article J Am Coll Cardiol · March 3, 2026 BACKGROUND: For >60 years, beta-blockers have been first-line therapy for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), although limited data support this recommendation. The MAPLE-HCM trial showed greater improvement in exercise capacity and ... Full text Link to item Cite

Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy.

Journal Article J Am Coll Cardiol · March 3, 2026 BACKGROUND: The cardiac myosin inhibitor aficamten was significantly more effective than metoprolol at improving exercise tolerance in MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), a head-to-head, intern ... Full text Link to item Cite

View All Publications

Recent Grants

Percutaneous or Surgical Mitral Valve Repair in Patients with Primary Mitral Regurgitation whose mitral valve has been determined to be suitable for correction by MV repair surgery

Clinical TrialPrincipal Investigator · Awarded by Evalve, Inc · 2021 - 2033

Discover- HCM

Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2022 - 2030

Machine Learning Guided Precision Genetic Testing for Identification of Monogenic Cardiovascular Disorders

ResearchCo Investigator · Awarded by National Heart, Lung, and Blood Institute · 2024 - 2028

View All Grants

Education

Duke University · 1990 M.D.